Biodistribution and dosimetry of 88Y (and equimolar 90Y) Janus-dodecanetetraacetic acid
(DOTA) were performed using a three-step pretargeting protocol in BALB/c mice bearing …

Three-step pretargeting for radioimmunotherapy in BALB/c mice with KHJJ tumors was done
with monoclonal antibody (mAb) 2D12. 5, which is specific for yttrium-1, 4, 7, 10 …

Pretargeted radioimmunotherapy permits the administration of doses of 90Y five times
higher than is possible with antibodies directly labeled with 90Y ttrium (90Y). These high …

Pretargeting involves administration of a tumor-targeting monoclonal antibody (mAb)
covalently linked to a molecule having a high-affinity binding site for a rapidly distributed …

90Yttrium-labeled monoclonal antibodies (mAbs) are likely to be important to
radioimmunotherapy (RAIT) of a variety of cancers. The goal of this study was to select and …

Radioimmunotherapy (RIT) is currently being considered for the treatment of solid tumors.
Although results have been encouraging for pretargeted 131I RIT with the affinity …

Aim: Fractionation is generally used as a mean to improve radioimmunotherapy (RIT). Since
RIT is considered suitable for small-volume disease, the aim of the current study was to …

A series of anti-tumor/anti-chelate bispecific antibody formats were developed for pre-
targeted radioimmunotherapy. Based on the anti-carcinoembryonic antigen humanized …

Radioimmunotherapy of solid malignancies using directly labelled 90 Y-monoclonal
antibodies has been associated in clinical trials with dose-limiting bone marrow toxicity. Our …

Radioimmunotherapy, an approach using radiolabeled antibodies, has had minimal
success in the clinic with several β-emitting radionuclides for the treatment of ovarian …